Vol 12, No 9 (September 30, 2023): Translational Lung Cancer Research

Are current lung cancer screening guidelines and programs racially biased?

The role of laboratory tests as a prognostic marker for immune-checkpoint therapy in non-small cell lung cancer

Differences and similarities of GTF2I mutated thymomas in different Eurasian ethnic groups

Are radiomic signatures ready for incorporation in the clinical pipeline?

Thyroid transcription factor-1 (TTF-1) expression and the efficacy of combination therapy with immune checkpoint inhibitors and cytotoxic chemotherapy in non-squamous non-small cell lung cancer

Characteristics and prognostic analysis of patients with detected KRAS mutations in resected lung adenocarcinomas by peptide nucleic acid-locked nucleic acid polymerase chain reaction (PNA-LNA PCR) clamp method

HSP90 expression is associated with outcome in pulmonary carcinoid tumor patients

Risk factors for symptomatic malignant pleural effusion recurrence in patients with actionable mutations in advanced lung adenocarcinoma

The differential prognostic implications of PD-L1 expression in the outcomes of Filipinos with EGFR-mutant NSCLC treated with tyrosine kinase inhibitors

Real-world clinical evidence of lazertinib use in acquired EGFR T790M mutated non-small cell lung cancer

Combined indocyanine green and medical glue enables stable and precise position in animal studies: promising for fluorescence-guided pulmonary ground glass nodule resection

Superior clinical outcomes in patients with non-small cell lung cancer harboring multiple ALK fusions treated with tyrosine kinase inhibitors

First-line versus second-line use of pralsetinib in treatment of rearranged during transfection (RET) fusion-positive advanced non-small cell lung cancer: a cost-effectiveness analysis

Characterization of the tumor microenvironment by single-cell RNA sequencing in non-small cell lung cancer treated with neo-adjuvant immunotherapy